Tango Therapeutics, Inc. — Director's Dealing 2021

Aug 13, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Tango Therapeutics, Inc. (TNGX)
CIK: 0001819133
Period of Report: 2021-08-10

Reporting Person: Third Rock Ventures IV, L.P. (10% Owner)
Reporting Person: Third Rock Ventures GP IV, L.P. (10% Owner)
Reporting Person: TRV GP IV, LLC (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	19363975	Direct

Footnotes

F1: On August 10, 2021, Tango Therapeutics, Inc. (f/k/a BCTG Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which BCTG Merger Sub Corp., a wholly-owned subsidiary of the Issuer merged with and into Tango Therapeutics, Inc. ("Tango"). At the effective time of the Business Combination, each share of Tango outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an exchange ratio of approximately 0.34. As a result, the Reporting Persons received 19,363,975 shares of the Issuer's Common Stock in consideration for the equity securities of Tango held by the Reporting Persons prior to the Business Combination.

F2: These shares are directly held by TRV IV. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.